Patients with scalp and body psoriasis who used nonsteroidal roflumilast foam .3% once daily experienced significant symptom improvement as early as 2 weeks.
13.10.2023 - Once-daily, steroid-free roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints compared to vehicleNew data highlights a significant reduction in scalp itch observed as early as 24 . Seite 1
Deciding on treatment, treatment side effects, self-image issues, topical regimen adherence, and quantification of disease were among the topics addressed by experts.
Late-breaking survey data from RAD 2023 show patients who achieve significant and quick response to itchy symptoms and lesion clearance are happier with their treatment regimen.
In her presentation at the Revolutionizing Atopic Dermatitis conference, Dr. Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 non-steroidal topicals.